Infertility Drugs and Devices used for treating infertility in male and female. Factors such as endometriosis, ovarian disorders, uterine disorders, tubal disorders, and hormonal disorders are the major cause of female infertility, whereas male infertility is caused by azoospermia, varicocele, ejaculation disorders, and erectile dysfunction. Treatment procedure constitutes of drugs, Assisted Reproductive Technology (ART), surgery, artificial insemination, and in vitro fertilization. Increasing prevalence of erectile dysfunction, increasing research and development, new product approval, and adoption of expansion strategies from major players operating in the market is expected to propel the market growth during the forecast period.
Key features of the study:
- This report provides in-depth analysis of the Global Infertility Drugs and Devices market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the Global Infertility Drugs and Devices market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Dare Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The Global Infertility Drugs and Devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Infertility Drugs and Devices market
Detailed Segmentation:
- Global Infertility Drugs and Devices Market, By Type:
- Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
- Infertility Devices
- Global Infertility Drugs and Devices Market, By Gender:
- Global Infertility Drugs and Devices Market, By Region:
- North America
- By Type:
- Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
- Infertility Devices
- Equipment
- Accessories
- By Gender
- Male
- Female
- By Country
- U.S.
- Canada
- Latin America
- By Type:
- Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
- Infertility Devices
- Equipment
- Accessories
- By Gender
- Male
- Female
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Type:
- Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
- Infertility Devices
- Equipment
- Accessories
- By Gender
- Male
- Female
- By Country
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- By Type:
- Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
- Infertility Devices
- Equipment
- Accessories
- By Gender
- Male
- Female
- By Country
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Type:
- Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
- Infertility Devices
- Equipment
- Accessories
- By Gender
- Male
- Female
- By Country
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- By Type:
- Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
- Infertility Devices
- Equipment
- Accessories
- By Gender
- Male
- Female
- By Country
- North Africa
- Central Africa
- South Africa
- Company Profiles
- Apricus Biosciences, Inc. *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bayer AG
- Cristalia Produtos Quimicos Farmaceuticos Ltda.
- Dong-A Pharmaceutical Co. Ltd.
- Eli Lilly and Company
- Meda Pharmaceuticals, Inc.
- Pfizer, Inc.
- S.K. Chemicals Co. Ltd.
- Vivus, Inc.
- Mylan Pharmaceuticals Inc.
- Ferring Pharmaceuticals
- Cipla Ltd
- Aspargo Laboratories, Inc.
- Aurobindo Pharma Ltd.
- Lupin Limited
- Novartis International AG
- Dare Bioscience, Inc.
- Torrent Pharmaceuticals Ltd.
- Alembic Pharmaceuticals
- Dr. Reddys Laboratories Ltd
- "*" marked represents similar segmentation in other categories in the respective section.